Table 5.

Key advantages and disadvantages of emerging high‐plex (> 10) IHC platform

Multiplexed solutions	Key advantages	Key disadvantages
GeoMx® DSP (DNA barcode technology)	40‐plex staining Clinical relevance +700 mRNA in situ detection No autofluorescence and spectral overlap Bundled image acquisition and analytical software	Limited ROIs Resolution (10–20 µm) No image construction
CODEX ® (DNA barcode technology)	40‐plex staining No spectral overlap Single‐cell data High resolution Low cost add‐on to existing imaging platforms Bundled image acquisition and analytical software	Low publication record
InSituPlex ® (DNA barcode technology)	>16‐plex Retains tissue integrity Reagent only platform No spectral overlap	Requires manual or existing automated staining platforms Requires existing or third‐party imaging and analysis platform Comparatively low plex
Hyperion (Imaging mass cytometry)	>40 markers simultaneously No autofluorescence and spectral overlap Single‐cell data ~0.5 µm resolution	Number of simultaneous markers is limited to existing heavy metals Low throughput Requires existing or third‐party analysis software
MACSima™ (Imaging cyclic staining technology)	Multiplexing of 100+ antibodies Fully automated all‐in‐one workflow > 1500 validated antibodies Single‐cell data Bundled image acquisition and analytical software	High costs associated with instrument, reagents and antibodies Low publication record
MIBIscope™ (Multiplexed Ion Beam Imaging technology)	>40 markers simultaneously No autofluorescence and spectral overlap Single‐cell data ~0.5 µm resolution Whole slide scanning Bundled image acquisition and analytical software	Number of simultaneous markers is limited to existing heavy metals Low throughput